Related Experiment Videos
Beneficial effects of octreotide in a patient with a metastatic paraganglioma
European Journal of Cancer (Oxford, England : 1990)
|April 1, 1996
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Anterior cruciate ligament reconstruction with semitendinosus graft, comparative study of two tibial fixation devices.
Acta orthopaedica Belgica·2025
Outbreak of hemolytic uremic syndrome with unusually severe clinical presentation caused by Shiga toxin-producing Escherichia coli O26:H11 in France.
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2022
[Early-onset neonatal infection: assessment of professional practices in 14 maternity wards in the Île-de-France region in 2013].
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2015
Kinetics and dynamics of cyclosporine A in three hepatic cell culture systems.
Toxicology in vitro : an international journal published in association with BIBRA·2015
Outcomes of CD20-targeting CAR T-cell therapy in patients with advanced melanoma: MB-CART20.1 Melanoma phase I trial.
European journal of cancer (Oxford, England : 1990)·2026
Diagnostic challenges in WHO classification of thymic epithelial tumors: The clinical value of an international expert pathology panel.
European journal of cancer (Oxford, England : 1990)·2026
A new era in anti-RAS therapy: Unique challenges and opportunities for radiotherapy clinical trials.
European journal of cancer (Oxford, England : 1990)·2026
What does addressing cancer inequalities really mean? Five principles that can drive global action.
European journal of cancer (Oxford, England : 1990)·2026
Acute and long-term outcomes of CD20-targeting CAR T-cell therapy in relapsed or refractory B-NHL: MB-CART20.1 Lymphoma phase I trial.
European journal of cancer (Oxford, England : 1990)·2026
Combined pharmacologic and lifestyle intervention for breast cancer prevention: Results of the randomized phase II TOLERANT trial in high-risk women.
European journal of cancer (Oxford, England : 1990)·2026
Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".
Current oncology (Toronto, Ont.)·2026
Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.
Current oncology (Toronto, Ont.)·2026
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Current oncology (Toronto, Ont.)·2026
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
Current oncology (Toronto, Ont.)·2026